BG-C137
- Generic Name
- BG-C137
A First-in-Human Study of BG-C137, an Anti-FGFR2b Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 68
- Registration Number
- NCT06625593
- Locations
- 🇰🇷
Samsung Medical Center, GangnamGu, Seoul Teugbyeolsi, Korea, Republic of
🇰🇷Asan Medical Center, SongpaGu, Seoul Teugbyeolsi, Korea, Republic of
🇺🇸Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath